New Therapeutic Approach Against BK Virus Infection Based on Monoclonal Antibodies

BK virus (BKV) infection has a major negative impact on transplant recipients. No BKV-specific antiviral therapy is available, so there is an urgent need to develop new anti-BKV preventive and therapeutic strategies.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

BK Virus Infection

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service de Virologie - CHU Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Samira FAFI-KREMER, PUPH

CONTACT

[email protected]

0369551438

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

BK positive
adult
ok to participed to research

Exclusion criteria

under guardianship
under curatorship
opposed to research
deprived of liberty

Treatment and study plan

Primary outcomes

Ability of the isolated monoclonal antibodies to neutralize all 3 BKV genotypes

Time frame: 5 years

The neutralization titer will be defined as the dilution of the sample that produced 50% inhibition of pseudovirion infectivity (IC50)

Study contacts

Contact information is provided by the study sponsor or research team.

Anne-Sophie U GEY

CONTACT

[email protected]

+33 388116684

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: AcMBK

Important dates

Study start: 2022
Primary completion: 2022
Study completion: 2025
First posted: Mar 3, 2022
Registry last updated: Aug 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting